Discrimination between parkinsonian syndrome and essential tremor using artificial neural network classification of quantified datscan data

Nuclear Medicine Communications

Volumn 27, Issue 12, 2006, Pages 939-944

  Hamilton, David ^a   List, Adrian ^a   Butler, Timothy ^a   Hogg, Stephen ^a   Cawley, Martin ^b  

^a Medical Physics Department   (United Kingdom)

^b LINCOLN COUNTY HOSPITAL   (United Kingdom)

Author keywords

Artificial neural network; Classification; DaTSCAN; Essential tremor; Parkinsonian syndromes; Quantification

Indexed keywords

N OMEGA FLUOROPROPYL 2BETA CARBOXYMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; ARTIFICIAL NEURAL NETWORK; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; ESSENTIAL TREMOR; FEMALE; HUMAN; MALE; PARKINSONISM; PUTAMEN; QUANTITATIVE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CLUSTER ANALYSIS; DIAGNOSIS, DIFFERENTIAL; ESSENTIAL TREMOR; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; NEURAL NETWORKS (COMPUTER); PARKINSON DISEASE; PATTERN RECOGNITION, AUTOMATED; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SYNDROME; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 33750742767     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/01.mnm.0000243369.80765.24     Document Type: Article

References (23)

1. Baker MG, Brooks DJ, Burn DJ, Chaudhuri KR, Findley LJ, Grosset DG, et al. DaTSCAN-SPECT diagnostic imaging in the management of Parkinson's disease. A consensus report. London: Parkinson's Disease Society, 2001.
2. 123I-FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997; 62:133-140.
3. 123I-FP-CIT SPECT. J Neural Transm 2000; 107:543-552.
4. Habraken JB, Booji J, Slomka P, Sokole Busemann E, van Royen EA. Quantification and visualization of defects of the functional dopaminergic system using an automatic algorithm. J Nucl Med 1999; 40:1091-1097.
5. 123I-labelled D2 transporter ligands. Eur J Nucl Med Mol Imaging 2002; 26:BP30-35.
6. 123I] β-CIT and SPECT in Parkinson's disease. J Nucl Med 1997; 38:1-6.
7. 123I] β-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Commun 2000; 21:417-424.
8. Verhoeff NP, Kapucu O, Sokole-Busemann E, van Royen EA, Janssen AG. Estimation of dopamine D2 receptor binding potential in the striatum with iodine-123-IBZM SPECT: technical and interobserver variability. J Nucl Med 1993; 34:2076-2084.
9. Kim SE, Lee WY, Choe YS, Kim JH. SPECT measurement of iodine-123-beta-CIT binding to dopamine and serotonin transporters in Parkinson's disease: correlation with symptom severity. Neurol Res 1999; 21:255-261.
10. 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000; 15:692-698.
11. 123I-FP-CIT study group. Mov Disord 2000; 15:503-510.
12. Winogrodzka A, Bergmans P, Booij J, van Royen EA, Janssen AG, Wolters EC. [I123]FP-CIT SPECT is a useful method to monitor the rate of dopaminergic degeneration in early-stage Parkinson's disease. J Neural Transm 2001; 108:1011-1019.
13. Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer's disease using a dopaminergic presynaptic ligand. J Neurol Neurosurgery Psychiatry 2002; 73:134-140.
14. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy. Neurol Sci 2003; 24:149-150.
15. Morton RJ, Guy MJ, Marshall CA, Clarke EA, Hinton PJ. Variation of DaTSCAN quantification between different gamma camera types. Nucl Med Commun 2005; 26:1131-1137.
16. Morton RJ, Guy MJ, Claus R, Hinton PJ, Marshall CA, Clarke EA. Comparison of different methods of DaTSCAN quantification. Nucl Med Commun 2005; 26:1139-1146.
17. Popperl G, Radau P, Linke R, Hahn K, Tatsch K. Diagnostic performance of a 3-D automated quantification method of dopamine D2 receptor SPECT studies in the differential diagnosis of parkinsonism. Nucl Med Commun 2005; 26:39-43.
18. Lokkegaard A, Werdelin LM, Friberg L. Clinical impact of diagnostic SPET investigations with a dopamine re-uptake ligand. Eur J Nucl Med 2002; 29:1623-1629.
19. 123I] β-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38:589-598.
20. 123I-FP-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm 1998; 105:1213-1228.
21. Dawson MRW, Dobbs A, Hooper HR, McEwan AJB, Triscott J, Cooney J. Artificial neural networks that use single-photon emission tomography to identify patients with probably Alzheimer's disease. Eur J Nucl Med 1994; 21:1303-1311.
22. Chan KH, Johnson KA, Becker JA, Satlin A, Mendelson J, Grarada B, Holman BL. A neural network classifier for cerebral perfusion imaging. J Nucl Med 1994; 35:771-774.
23. Radau PE, Linke R, Slomka PJ, Tatsch K. Optimization of automated quantification of I123-IBZM uptake in the striatum applied to parkinsonism. J Nucl Med 2000; 41:220-227.